HoFH – Homozygous Familial Hypercholesterolemia

CME: 1.0

April 15, 2022
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This activity is designed to meet the educational needs of cardiologists, lipidologists, internists, primary care providers, infusion center nurses, and other healthcare providers who treat patients with FH.

Program Overview

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder that results in markedly high levels of LDL-C in patients and increased risk of cardiovascular disease and premature mortality. Despite improved understanding of underlying genetic causes and improved strategies for reducing LDL-C, HoFH is still underdiagnosed and undertreated. Because earlier initiation of therapies are associated with improved patient outcomes, it is vital that clinicians diagnose and treat HoFH as soon as possible. However, persistent gaps in clinician identification of HoFH symptoms, lack of awareness of appropriate therapies to use in HoFH patients, and barriers to access to recommended care have resulted in suboptimal treatment of HoFH. Therefore, we propose an activity designed for clinicians who diagnose and treat HoFH patients to close these gaps and improve HoFH patient outcomes and quality of life.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the signs, symptoms, and diagnostic markers of familial hypercholesterolemia
  • Describe current guidelines for the treatment of HoFH
  • Compare and contrast current treatment options for HoFH
  • Formulate care strategies that incorporate patient needs and potential barriers to treatment

Post a comment to this article